Lawsuits seeking damages from the makers of Xarelto, Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson), have surpassed 3,000 in number with many plaintiffs alleging they suffered similar harm resulting from taking the drug, reports the Digital Journal.
The U.S. Judicial Panel on Multidistrict Litigation elected to merge 2,800 individual cases into a multidistrict litigation (MDL) with the purpose of expediting the process. The MDL has been consolidated in U.S. District Court for the Eastern District of Louisiana. A similar situation occurred in Pennsylvania, where 550 cases merged to form a mass tort program, coordinated by the Philadelphia Court of Common Pleas.
The reasoning behind these combinations lies in the similarity of allegations brought against the drug manufacturers. People claim that neither they nor their physicians were sufficiently apprised of the potential elevated risk for the occurrence of sudden dangerous bleeding events associated with taking Xarelto. They were therefore, placed in danger of serious harm without due knowledge, according to the Digital Journal.
In 2011, the U.S. Food and Drug Administration (FDA) granted approval to Xarelto for the treatment of individuals suffering from pulmonary embolism or deep vein thromboses and for those recovering from hip or knee replacement surgery. Shortly thereafter, its approval was expanded to treat those with atrial fibrillation, a heart condition that increases the potential for stroke.